
	Where results make sense

Topic: Janssen Ortho Inc

	VCU by Janssen-Ortho Inc
		Ortho 7/7/7 is a patented medicine being sold in Canada by Janssen Ortho Inc. (Janssen-Ortho).
		Ortho 7/7/7, (norethindrone-ethinyl, estradiol) is an oral contraceptive.
		This patent was granted to Ortho Pharmaceutical Corp., USA on September 1, 1987 and expired on September 1, 2004.
	www.pmprb-cepmb.gc.ca /english/View.asp?x=486&mp=271 (446 words)

	Janssen: Exclusively Dedicated to Mental Health
		Based in Titusville, New Jersey, U.S., Janssen, L.P. is focused exclusively on mental health and markets prescription medications for the treatment of schizophrenia and bipolar mania.
		The focus of our Janssen vision ensures we will continue to deliver innovative products, and deepen our partnerships with healthcare professionals, patients, and caregivers within the mental health community.
		Janssen, L.P. recognizes that the Internet is a global communications medium; however, laws, regulatory requirements and medical practices for pharmaceutical products vary from country to country.
	www.janssen.com (193 words)

	Prepulsid (Cisapride) Labelling Revised In Canada
		Prepulsid is a prescription drug that is approved for use in the symptomatic treatment of gastrointestinal motility disorders, including gastroesophageal reflux disease (GERD), delayed emptying of the stomach, and certain conditions involving the function of the intestinal tract.
		Janssen-Ortho Inc. is now recommending that in the treatment of GERD, the drug should generally be reserved for patients who do not adequately respond to lifestyle modifications or other measures such as antacids or acid reducing agents.
		Janssen-Ortho Inc. and Health Canada are continuing to monitor and evaluate the risks and benefits associated with the use of Prepulsid to ensure its most appropriate use.
	www.docguide.com /dg.nsf/PrintPrint/426DDFDDA8F7F53B852568950070D081 (670 words)

	Janssen, Ortho-McNeil, fellowship program for Jefferson Medical College (Site not responding. Last check: 2007-11-01)
		The goal of the Ortho-McNeil Janssen Scientific Affairs, L.L.C. Outcomes Research Fellowship is to prepare the individual for a career as an analyst, educator and consultant in healthcare outcomes research.
		To educate the fellow on economic and health-related quality of life principles and applications, and demonstrate their use in evaluating costs and outcomes relative to healthcare interventions.
		Selection of the fellow will be on a competitive basis from a national pool of candidates with scientific and/or clinical training in healthcare and an interest in outcomes research.
	www.janssen.com /html/cjan/company_career-fellowship.jsp (848 words)

	Johnson & Johnson India
		Centocor, Inc., is a leading biopharmaceutical company that creates, acquires and markets cost-effective therapies that yield long-term benefits for patients and the health care community.
		Janssen-Ortho Inc., located in Toronto, Ontario, is one of Canada's major pharmaceutical companies focusing on key therapeutic areas that include psychiatry, women's health, oncology, nephrology, infectious diseases, gastroenterology, erectile dysfunction and active wound healing.
		Janssen Pharmaceutica was established in 1953 in Belgium (Beerse) by a young medical doctor, Dr Paul Janssen.
	www.jnjindia.com /janssen_intsites.asp (634 words)

	Notice : 17 Oct 2002 Health Canada - Drug Safety Update - Risperdal® (Site not responding. Last check: 2007-11-01)
		Further to discussions with Health Canada, Janssen-Ortho Inc. advised healthcare professionals of new safety information for the use of RISPERDAL (risperidone), an antipsychotic medication in elderly, dementia patients.
		Recent analysis of some clinical trials in elderly patients with dementia suggests that the use of RISPERDAL in dementia patients may be associated with an increased incidence of reports of cerebrovascular adverse events (CVAEs) such as stroke and transient ischemic attacks (TIAs), including fatalities.
		Janssen- Ortho Inc. is committed to providing you with the most current and complete product information available for the management of patients receiving RISPERDAL.
	www.ocpinfo.com /client/ocp/ocphome.nsf/1071f947e728982c85256ac700690097/8b46aa5fbdfc090685256cc200693471?OpenDocument (1323 words)

	Study Reveals Dangerous Myths About The Pill (Site not responding. Last check: 2007-11-01)
		For example, BOAS, conducted by Janssen-Ortho Inc. with the assistance of the Society of Obstetricians and Gynaecologists of Canada (SOGC), found 27 per cent of the 6,224 women participants believe the pill increases the risk of cancer.
		Janssen-Ortho Inc., located in North York, Ontario, is a research-based pharmaceutical company with a broad range of pharmaceuticals used in family planning, psychiatry, dermatology, gastroenterology, oncology and treatment of infections.
		Janssen-Ortho Inc., working with some of Canada's foremost experts in gynaecology and obstetrics, took the initiative to fill the education gap, developing a counselling and education service unlike any currently available.
	www.pslgroup.com /dg/E466.htm (1211 words)

	New low dose birth control pill now available in Canada : ArriveNet Press Releases : Business (Site not responding. Last check: 2007-11-01)
		About Janssen-Ortho Janssen-Ortho Inc. is a brand-name pharmaceutical company headquartered in Toronto with a broad range of medications used in women's health, psychiatry, neurology, dementia, attention deficit hyperactivity disorder, pain management, infectious disease, gastroenterology, and urology.
		Ortho Pharmaceutical was one of the first companies in Canada to make oral contraceptives.
		Comparison of a novel norgestimate/ethinyl estradiol oral contraceptive (Ortho Tri-Cyclen Lo) with the oral contraceptive Loestrin Fe 1/20.
	press.arrivenet.com /business/article.php/611607.html (1092 words)

	Ortho-McNeil Pharmaceutical, Inc., To Acquire Marketing Rights To AXERT® (almotriptan malate) For Migraine ...
		Ortho-McNeil Pharmaceutical, Inc., a subsidiary of Johnson and Johnson, is based in Raritan, NJ.
		In December 2002, Ortho-McNeil Pharmaceutical, Inc., submitted a supplemental new drug application (sNDA) to the FDA to market TOPAMAX® for the prevention of migraine headaches in adults.
		In addition, Ortho-McNeil Pharmaceutical, Inc., filed an application for TOPAMAX® as stand-alone therapy (monotherapy) in adults and children age six and older with newly diagnosed epilepsy in October 2002.
	www.jnj.com /news/jnj_news/20030415_164701.htm?pageTemplate=printer_friendly.jsp&contentPage=/news/news_content.jsp (1079 words)

	Cannabis-Based Spray Relieves MS
		Letrozole is supplied in Canada by Novartis Pharmaceuticals Canada Inc. In 2001, Health Canada approved the drug as first-line treatment of advanced breast cancer in postmenopausal women.
		Fragmin Solution Use: thrombosis Pfizer Canada Inc., maker of the anticoagulant Fragmin (dalteparin), announced it has been approved to prevent the recurrence of venous thromboembolism in patients with cancer.
		The cumulative rate of recurrent VTE events over a six-month period was reduced from 17.4% in the warfarin group to 8.8% in the Fragmin group.
	www.mapinc.org /drugnews/v05/n833/a09.html (675 words)

	Class action launched against contraceptive patch maker Janssen-Ortho Inc. (Site not responding. Last check: 2007-11-01)
		The statement of claim alleges doctors and patients were not adequately warned that Ortho Evra has been associated with an increased risk of developing blood clots, pulmonary emboli, strokes,heart attacks and deep vein thrombosis.
		Ortho Evra was first approved for marketing and sale in Canada as a contraceptive patch in 2002.
		In March, Health Canada said it is currently reviewing the results of two studies which looked at the risk of serious side effects when using Ortho Evra.
	www.cbc.ca /cp/health/060728/x072804.html (154 words)

	Ortho-McNeil Pharmaceutical, Inc. to Acquire Marketing Rights to AXERT(R) For Migraine Headaches
		Completion of the transaction, which is expected to occur during the second quarter of 2003, is subject to expiration of the applicable waiting period under the Hart-Scott-Rodino Act.
		AXERT fulfills all of these patient needs." Ortho-McNeil Pharmaceutical, Inc., a Johnson & Johnson company, is based in Raritan, N.J. The company markets prescription medications in several therapeutic categories including central nervous system, infectious disease, urology, pain and women's health.
		About AXERT In clinical trials, AXERT has been shown to be an effective treatment for migraine headaches, with the incidence of side effects comparable to placebo (sugar pill).
	www.prnewswire.com /cgi-bin/stories.pl?ACCT=104&STORY=/www/story/04-15-2003/0001926905&EDATE= (978 words)

	Ortho-McNeil, Inc.: Innovative, High Quality, Safe and Effective Treatments to Advance Patient Care (Site not responding. Last check: 2007-11-01)
		Ortho-McNeil, Inc. strives to provide innovative, high quality, safe and effective treatments to healthcare professionals in primary care, hospitals and other care facilities.
		Ortho-McNeil, Inc. is a healthcare company that draws on the rich patient care heritage of its two sister companies, Ortho-McNeil Pharmaceutical, Inc. and Janssen, L.P. Ortho-McNeil strives to provide innovate, high quality, safe and effective treatments to advance patient care.
		Ortho-McNeil, Inc. recognizes that the Internet is a global communications medium; however, laws, regulatory requirements and medical practices for pharmaceutical products vary from country to country.
	www.orthomcneil.com (290 words)

	'+alt+'
		From the top ranks to the trenches, there was enthusiastic support for this endeavor, and in the process of articulating our case, we forged new friends and audiences for the Dittrick.
		The stem of the cup is shaped like a dried beaver testicle, which was steeped in alcohol and the resulting brew consumed for its contraceptive qualities by women in New Brunswick, Canada.
		The base of the cup is shaped in the form of an Ortho DIALPAK ® tablet dispenser, adopted in 1962 by Ortho Pharmaceutical for its first oral contraceptive, Ortho-Novum.
	www.case.edu /artsci/dittrick/site2/news/contrareception.htm (678 words)

	ORTHO EVRA
		Hormones from patches applied to the skin get into the blood stream and are removed from the body differently than hormones from birth control pills taken by mouth.
		However, it is not known if there are differences in the risk of serious side effects based on the differences between ORTHO EVRA and a birth control pill containing 35 micrograms of estrogen.
		You should discuss with your healthcare professional whether ORTHO EVRA is a good method of contraception for you.
	www.orthoevra.com /prescribing/prescribing.html (482 words)

	[No title]
		The Planned Parenthood Federation of Canada (PPFC), in collaboration with Janssen-Ortho Inc., is pleased to announce that Leslie Shaw, a long time volunteer with Planned Parenthood Metro Clinic in Halifax, has been selected as the 2004 Janssen-Ortho Inc. Volunteer of the Year.
		The Planned Parenthood Federation of Canada (PPFC), in collaboration with Janssen-Ortho Inc., is pleased to announce that Sharon Froese, a long time volunteer and social justice activist with Planned Parenthood Cape Breton, has been selected as the 2003 Janssen-Ortho Inc. Volunteer of the Year.
		The Planned Parenthood Federation of Canada (PPFC), in collaboration with Janssen-Ortho Inc., is pleased to announce that Dr. Violet Shadd, a long time volunteer with Planned Parenthood Waterloo Region (PPWR), has been selected as the 2002 Janssen-Ortho Inc. Volunteer of the Year.
	www.ppfc.ca /ppfc/content.asp?articleid=123&mode=print (1264 words)

	Medication errors involving Reminyl and Amaryl Janssen-Ortho Inc. and Aventis Pharma Inc
		Janssen-Ortho Inc. is a research-based pharmaceutical company located in Toronto, Ontario.
		Aventis Pharma Inc. is a research-based pharmaceutical company located in Laval, Quebec.
		The identification, characterization, and management of marketed health product-related adverse reactions are dependent on the active participation of health care professionals in adverse reaction reporting programmes.
	www.hc-sc.gc.ca /dhp-mps/medeff/advisories-avis/public/2004/reminyl_amaryl_pa-ap_e.html (879 words)

	Important New Safety Information SPORANOX (itraconazole) - Janssen-Ortho Inc.
		Janssen-Ortho Inc. is committed to providing you with the most current product information available for the management of your patients receiving SPORANOX.
		In addition, you can further our understanding of adverse events by reporting all cases to Janssen-Ortho Inc. at 1-800-567-3331 and to Health Canada following the instructions provided in Appendix 7A, p.
		The ADR Reporting Form can be found in The Canadian Compendium of Pharmaceutical and Specialties, or on the TPD website, along with the ADR Guidelines.
	www.hc-sc.gc.ca /dhp-mps/medeff/advisories-avis/prof/2001/sporanox_hpc-cps_e.html (627 words)

	Prepulsid
		PREPULSID, marketed by Janssen-Ortho Inc., is a prescription drug indicated for the treatment of gastroparesis, intestinal pseudo-obstruction, and gastroesophageal reflux disease which is refractory to lifestyle modifications, antacids, and gastric acid reducing agents.
		In accordance with the requirements of the Special Access Program the prescribing physician has the responsibility to determine if the benefits of treatment outweigh the risk of serious cardiac adverse events.
		Janssen-Ortho Inc. has indicated to Health Canada that it will limit the availability of PREPULSID to those patients who have little or no alternative to PREPULSID as a treatment for their debilitating and possibly life-threatening conditions.
	www.napra.org /docs/0/310/320.asp (538 words)

	CNW Group
		Janssen-Ortho Inc. is a research-based pharmaceutical company located in Toronto, Canada.
		Reporting rates determined on the basis of spontaneously reported post- marketing adverse events are generally presumed to underestimate the risks associated with drug treatments.
		The identification, characterization, and management of marketed health product-related adverse reactions are dependent on the active participation of health care professionals in adverse drug reaction reporting programmes.
	www.newswire.ca /en/releases/archive/September2005/16/c0586.html (752 words)

	HealthConnect (Site not responding. Last check: 2007-11-01)
		TORONTO, Feb. 11 /CNW/ - Janssen-Ortho Inc. today announced that REGRANEX(x) becaplermin 0.01%, the first drug to actively stimulate wound healing, has been approved by Health Canada's Therapeutic Products Programme for the treatment of diabetic foot ulcers, the leading cause of amputation among Canadians with diabetes.
		REGRANEX is marketed in Canada by Janssen-Ortho Inc. Janssen-Ortho is a research-based pharmaceutical company in Toronto with a broad range of pharmaceuticals for use in anemia, infectious disease, psychiatry, neurology,
		Janssen-Ortho is dedicated to creating a better quality of life through clinical research, biotechnology and the development of innovative pharmaceuticals.
	www.healthconnect.ca /InformMe/articles.asp?ID=42 (542 words)

	Lexpert: Deal
		Justice Nadon of the Federal Court upheld an application by Janssen Pharmaceutica, a subsidiary of Johnson & Johnson, under the Patent Act to prevent Apotex from introducing the Apotex version of Janssen’s billion dollar drug Prepulsid (cisapride) into the market on the basis that the Apotex process was a chemical equivalent to the Janssen process.
		The Canadian litigation was the first challenge in the world of this patent.
		Counsel for Janssen were Anthony George Creber and Jennifer L. Wilkie of Gowling, Strathy & Henderson, and counsel for Apotex were Harry B. Radomski and Ivor Hughes, both of Goodman Philips & Vineberg.
	www.lexpert.ca /deal.php?id=1890 (148 words)

	Whitecap news - Janssen-Ortho Inc. Chooses Whitecap to Design New Corporate Intranet (Site not responding. Last check: 2007-11-01)
		Key elements of the Intranet are expected to be a powerful search engine to assist employees to quickly sort through and find specific information they seek from the wealth of company and product information available.
		To accomplish this goal, the Intranet will be seamlessly and securely integrated with Janssen’s back end SAP system, as well as other IT systems.
		This is an especially important project for Janssen-Ortho because it will really help employees to realize significant productivity gains in their day-to-day jobs, as well as enhance communications across the entire enterprise.
	www.whitecapcanada.com /09_2_092002.asp (348 words)

	CJP - March 2004 - Supplement (Site not responding. Last check: 2007-11-01)
		Dr Lam is not a major stockholder nor does he receive any other financial or material support with any organizations that could be perceived as a real or apparent conflict of interest in the context of the subject of this supplement article.
		Dr Chokka has received research funding and (or) is on the speakers bureau of AstraZeneca, Bristol Myers Squibb Canada Inc, Eli Lilly Canada Inc, Lundbeck Canada Inc, GlaxoSmithKline, Janssen Ortho Pharma, Pfizer Canada Inc, and Wyeth Canada.
		Dr Rabheru serves as a speaker and consultant for Janssen Ortho Inc, Pfizer Canada, AstraZeneca Canada, Novartis Canada, Lundbeck, Organon Canada, GlaxoSmithKline, Eli Lilly, and Wyeth.
	www.cpa-apc.org /Publications/CJP/supplements/march2004/Funding.asp (467 words)

	Ortho-McNeil Pharmaceutical : News Center (Site not responding. Last check: 2007-11-01)
		Each company independently sets its own level of savings and selects which products are included in the program, and its decisions are subject to change.
		The Johnson and Johnson companies participating in the program include Janssen Pharmaceutica Products, L.P., Janssen Ortho-McNeil Primary Care, Ortho-McNeil Neurology, McNeil Consumer and Specialty Pharmaceuticals, a division of McNeil-PPC, Inc., OrthoNeutrogena, a divison of Ortho-McNeil Pharmaceuticals, Inc., VISTAKON® Pharmaceuticals, LLC, and LifeScan, Inc.
		In introducing the Together Rx Access™ Card, the companies in Together Rx Access™, L.L.C., are applying their experience from launching the successful Together Rx Card, which has so far helped more than 1.5 million Americans over the age of 65 save more than $700 million on prescription drugs.
	www.ortho-mcneilpharmaceutical.com /news/article011105.html (800 words)

	Health Canada Endorses Important Safety Information Regarding Medication Errors Involving Reminyl (Galantamine ...
		As with all medications, Reminyl and Amaryl should not be used by anyone who does not require the drug to treat a disease or its symptoms.
		Any occurrences of prescribing or dispensing errors or other serious and/or unexpected adverse reactions in patients receiving Reminyl or Amaryl should be reported to Janssen-Ortho Inc. (for Reminyl), Aventis Pharma Inc. (for Amaryl) or Health Canada at the following addresses:
		Amaryl is a registered trademark of Aventis Group.
	www.docguide.com /dg.nsf/PrintPrint/E82A870A3341A87E85256F720050F4B7 (751 words)

	Ortho-McNeil, Inc.: Our Products (Site not responding. Last check: 2007-11-01)
		Following is a complete list of products for Ortho-McNeil, Inc. in the United States.
		The only way doctors can obtain cisapride is through a limited-access program developed together by Janssen Pharmaceutica and the U.S. Food and Drug Administration.
		This program was created to ensure that only appropriate patients receive the medication.
	www.ortho-mcneil.com /html/comi2/products_list.jsp (283 words)

Try your search on: Qwika (all wikis)